Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 11/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184449 | 0.94 | PTGER1 (0.49) | PTGER1ESR2LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL3186899 | 0.93 | PTGER1 (0.52) | PTGER1ESR2LMNAKMT2ACYP2C9 | |
| SCHEMBL3176691 | 0.91 | PTGER1 (0.57) | PTGER1ESR2CYP2C9 | |
| SCHEMBL3582433 | 0.89 | PTGER1 (0.63) | PTGER1CYP2C9 | |
| SCHEMBL3186031 | 0.89 | PTGER1 (0.52) | PTGER1ESR2CYP2C9 | |
| SCHEMBL3186073 | 0.87 | PTGER1 (0.45) | PTGER1ESR2CYP2C9 | |
| SCHEMBL3180343 | 0.87 | PTGER1 (0.50) | PTGER1ESR2KMT2ASMN1; SMN2CYP2C9 | |
| SCHEMBL3186149 | 0.86 | P2RY14 (0.44) | PTGER1ESR2 | |
| SCHEMBL3179360 | 0.86 | PTGER1 (0.49) | PTGER1ESR2LMNAKMT2ACYP2C9 | |
| SCHEMBL4090882 | 0.86 | PTGER1 (0.77) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022486-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022486-A1 | COMPOUNDS | SCD, CYP11B2, SCD5 | PTGER1 681/4885ESR2 2943/4885LMNA 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.